Donepezil found helpful in dementia with lewy bodies

July 31, 2012
Donepezil found helpful in dementia with lewy bodies
For patients with dementia with Lewy bodies, treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published in the July issue of the Annals of Neurology.

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published in the July issue of the Annals of Neurology.

Etsuro Mori, M.D., Ph.D., of the Tohoku University Graduate School of Medicine in Sendai, Japan, and colleagues conducted a randomized, double-blind, placebo-controlled trial involving 140 patients with DLB who received either placebo or 3, 5, or 10 mg of donepezil hydrochloride per day for 12 weeks (35, 35, 33, and 37 patients, respectively). Cognitive function was measured using the Mini-Mental State Examination (MMSE); were measured using the Neuropsychiatric Inventory; global function was evaluated using the Clinician's Interview-Based Impression of Change-plus Caregiver Input (CIBIC-plus); and caregiver burden was also assessed.

The researchers found that, compared with , the MMSE scores were significantly better with donepezil 5 mg (mean difference, 3.8) and 10 mg (mean difference, 2.4), but the 3 mg/day dose was not significantly better than placebo (P = 0.017). Donepezil at doses of 3, 5, and 10 mg/day correlated with significant improvements versus on CIBIC-plus. Both the 5 and 10 mg doses of donepezil resulted in significant improvements in . Caregiver burden also improved, but only with the 10 mg/day dose. The safety results were similar among the groups and were consistent with the known profile.

"Donepezil at 5 and 10 mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eisai Co., which funded the study and manufactures donepezil.

Explore further: Sumatriptan/Naproxen helpful in treating teens' migraines

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Sumatriptan/Naproxen helpful in treating teens' migraines

May 15, 2012
(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics.

Prophylaxis with apixaban feasible for cancer patients

March 29, 2012
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

ECO: New weight loss drug effective in advanced obesity

May 14, 2012
(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Experts challenge FDA over approval for new dose of Alzheimer's drug

March 22, 2012
Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts in the British Medical Journal today.

Belimumab deemed safe for long-term lupus treatment

June 19, 2012
(HealthDay) -- For patients with systemic lupus erythematosus (SLE), long-term belimumab therapy combined with standard therapy is well tolerated, according to a study published online June 5 in Arthritis & Rheumatism.

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Recommended for you

Study reveals breakthrough in decoding brain function

September 25, 2017
If there's a final frontier in understanding the human body, it's definitely not the pinky. It's the brain.

After 15 years in a vegetative state, nerve stimulation restores consciousness

September 25, 2017
A 35-year-old man who had been in a vegetative state for 15 years after a car accident has shown signs of consciousness after neurosurgeons implanted a vagus nerve stimulator into his chest. The findings reported in Current ...

Overturning widely held ideas: Visual attention drawn to meaning, not what stands out

September 25, 2017
Our visual attention is drawn to parts of a scene that have meaning, rather than to those that are salient or "stick out," according to new research from the Center for Mind and Brain at the University of California, Davis. ...

A brain system that builds confidence in what we see, hear and touch

September 25, 2017
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the ...

The rat race is over: New livestock model for stroke could speed discovery

September 25, 2017
It is well-known in the medical field that the pig brain shares certain physiological and anatomical similarities with the human brain. So similar are the two that researchers at the University of Georgia's Regenerative Bioscience ...

Brain guides body much sooner than previously believed

September 25, 2017
The brain plays an active and essential role much earlier than previously thought, according to new research from Tufts University scientists which shows that long before movement or other behaviors occur, the brain of an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.